10 research outputs found

    Phase II evaluation of MGBG in non-small cell carcinoma of the lung

    Full text link
    One hundred and eight patients with non-small cell lung cancer were treated in a Phase II trial with MGBG at a dose of 600 mg/m 2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 1/40 with squamous cell carcinoma. No responses were noted in 24 patients with large cell carcinoma. Overall, the drug was reasonably well-tolerated. At this dosage and schedule, MGBG has no substantial antitumor activity for patients with non-small cell lung cancer.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45128/1/10637_2004_Article_BF00180196.pd

    The 6-MP versus placebo clinical trial in acute leukemia

    No full text

    References

    No full text

    Classification of Chemotherapeutic Agents According to their Mechanisms of Action

    No full text
    corecore